Reuters logo
a month ago
BRIEF-Genkyotex announces investigator-initiated Phase 2 clinical trial to evaluate 48-week treatment with GKT831
June 28, 2017 / 4:19 PM / a month ago

BRIEF-Genkyotex announces investigator-initiated Phase 2 clinical trial to evaluate 48-week treatment with GKT831

1 Min Read

June 28 (Reuters) - GENKYOTEX SA:

* GENKYOTEX ANNOUNCES INVESTIGATOR-INITIATED PHASE 2 CLINICAL TRIAL TO EVALUATE 48-WEEK TREATMENT WITH GKT831 IN PATIENTS WITH TYPE 1 DIABETES AND KIDNEY DISEASE

* TRIAL IS EXPECTED TO BEGIN PATIENT ENROLLMENT DURING SECOND HALF OF 2017

* IN A PREVIOUS, SHORT-TERM PHASE 2 TRIAL IN PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE, GKT831 DEMONSTRATED AN EXCELLENT SAFETY PROFILE

* IN PREVIOUS SHORT-TERM PHASE 2 TRIAL GKT831 ACHIEVED STATISTICALLY SIGNIFICANT REDUCTIONS IN SEVERAL SECONDARY EFFICACY ENDPOINTS

* IN A PREVIOUS, SHORT-TERM PHASE 2 TRIAL IMPROVEMENTS IN ALBUMINURIA, STUDY'S PRIMARY EFFICACY ENDPOINT, WAS NOT ACHIEVED AFTER 12 WEEKS OF TREATMENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below